APD371

Cannabis Testing Services Market by Test Type, Product Type, End-users, and Region - Global Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022
Health, Biotechnology, Arena Pharmaceuticals, Industry, Biotechnology, Marketing, Patient, Stomach, Acquisition, APD371, CB2, Product type, CAGR, Pfizer, Region, US, HyperStealth Biotechnology Corporation, Adoption, Pharmaceutical industry, Olorinab

The "Cannabis Testing Services Market, by Test Type, by Product Type, by End-users, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabis Testing Services Market, by Test Type, by Product Type, by End-users, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing adoption of inorganic growth strategies such as acquisition by key players is expected to drive the market growth over the forecast period.
  • For instance, in December 2021, Pfizer Inc., multinational pharmaceutical and Biotechnology Corporation had acquired with the clinical-stage company Arena Pharmaceuticals, a Biotech Company.
  • Furthermore, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation had signed agreement for testing analysis with the clinical-stage company Arena Pharmaceuticals for a total equity value of around $6.7 billion.